# Summary of REMS for FDA-approved CAR T-cell products

## Abecma (idecabtagene vicleucel)
|CRS grade (Lee et al 2014)| Tocilizumab   | Corticosteroids |
:----:|     :----:    |  :----:         |
|Grade 1 (Lee 2014)| If onset 72 hours or more after infusion, treat symptomatically. If onset less than 72 hours after infusion, consider tocilizumab 8 mg/kg IV over 1 hour (not to exceed 800 mg).| Consider dexamethasone 10 mg IV every 24 hours.|
|Grade 2 (Lee 2014)|Administer tocilizumab 8 mg/kg IV over 1 hour (not to exceed 800 mg). Repeat tocilizumab every 8 hours as needed if not responsive to intravenous fluids or increasing supplemental oxygen. Limit to a maximum of 3 doses in a 24-hour period; maximum total of 4 doses.|Consider dexamethasone 10 mg IV every 12 to 24 hours.|

If no improvement within 24 hours or rapid progression, repeat tocilizumab and escalate dose and frequency of dexamethasone (20 mg IV every 6 to 12 hours). If no improvement within 24 hours or continued rapid progression, switch to methylprednisolone 2 mg/kg followed by 2 mg/kg divided 4 times per day. After 2 doses of tocilizumab, consider alternative anti-cytokine agents. Do not exceed 3 doses of tocilizumab in 24 hours, or 4 doses in total.
|
